CA2004935A1 - Anticorps monoclonaux anti-interleukines-1.alpha. et 1.beta., leur procede de production et applications desdits anticorps a la detection des interleukines-1.alpha. et 1.beta. et en therapeutique - Google Patents

Anticorps monoclonaux anti-interleukines-1.alpha. et 1.beta., leur procede de production et applications desdits anticorps a la detection des interleukines-1.alpha. et 1.beta. et en therapeutique

Info

Publication number
CA2004935A1
CA2004935A1 CA002004935A CA2004935A CA2004935A1 CA 2004935 A1 CA2004935 A1 CA 2004935A1 CA 002004935 A CA002004935 A CA 002004935A CA 2004935 A CA2004935 A CA 2004935A CA 2004935 A1 CA2004935 A1 CA 2004935A1
Authority
CA
Canada
Prior art keywords
beta
alpha
antibodies
ache
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002004935A
Other languages
English (en)
French (fr)
Inventor
Yveline Frobert
Jacques Grassi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Publication of CA2004935A1 publication Critical patent/CA2004935A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA002004935A 1988-12-08 1989-12-08 Anticorps monoclonaux anti-interleukines-1.alpha. et 1.beta., leur procede de production et applications desdits anticorps a la detection des interleukines-1.alpha. et 1.beta. et en therapeutique Abandoned CA2004935A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8816165A FR2640146B1 (fr) 1988-12-08 1988-12-08 Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
FR8816165 1988-12-08

Publications (1)

Publication Number Publication Date
CA2004935A1 true CA2004935A1 (fr) 1990-06-08

Family

ID=9372733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002004935A Abandoned CA2004935A1 (fr) 1988-12-08 1989-12-08 Anticorps monoclonaux anti-interleukines-1.alpha. et 1.beta., leur procede de production et applications desdits anticorps a la detection des interleukines-1.alpha. et 1.beta. et en therapeutique

Country Status (7)

Country Link
EP (1) EP0399024A1 (de)
JP (1) JPH04503600A (de)
CA (1) CA2004935A1 (de)
DE (1) DE399024T1 (de)
ES (1) ES2038571T1 (de)
FR (1) FR2640146B1 (de)
WO (1) WO1990006371A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015908D0 (en) * 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
EP0659766A1 (de) * 1993-11-23 1995-06-28 Schering-Plough Menschliche Monoklonalantikörper gegen menschliche Cytokine und Verfahren zur Herstellung dieser Antikörper
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
WO2007015128A1 (en) 2005-08-02 2007-02-08 Xbiotech Inc. DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1α AUTOANTIBODIES
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
KR101567117B1 (ko) 2008-05-30 2015-11-06 엑스바이오테크, 인크. 인터류킨-1 알파 항체 및 그의 사용 방법
CA2737056C (en) 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
KR20130108305A (ko) 2010-08-23 2013-10-02 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP6456015B2 (ja) * 2013-07-19 2019-01-23 国立大学法人三重大学 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
WO2018150265A1 (en) 2017-02-16 2018-08-23 Xbiotech, Inc. Treatment of hidradenitis suppurativa
EP3836954A1 (de) 2018-08-13 2021-06-23 Iltoo Pharma Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6291197A (ja) * 1985-10-17 1987-04-25 Dainippon Pharmaceut Co Ltd 抗ヒトインタ−ロイキン１抗体，その製法及びその使用法
ZA872784B (en) * 1986-05-01 1987-10-16 Immunex Corporation Detection of inflammation and novel antibodies therefor
DK590387A (da) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1

Also Published As

Publication number Publication date
FR2640146A1 (fr) 1990-06-15
ES2038571T1 (es) 1993-08-01
EP0399024A1 (de) 1990-11-28
JPH04503600A (ja) 1992-07-02
WO1990006371A1 (fr) 1990-06-14
FR2640146B1 (fr) 1993-12-24
DE399024T1 (de) 1991-04-11

Similar Documents

Publication Publication Date Title
CA2004935A1 (fr) Anticorps monoclonaux anti-interleukines-1.alpha. et 1.beta., leur procede de production et applications desdits anticorps a la detection des interleukines-1.alpha. et 1.beta. et en therapeutique
McCaffery et al. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
CA1182406A (en) Hybrid cell line for producing complement-fixing monoclonal antibody to human t cells, antibody, and methods
Clausen et al. Incompatible A antigen expressed in tumors of blood group O individuals: immunochemical, immunohistologic, and enzymatic characterization.
BE1000811A4 (fr) Anticorps monoclonaux, peptides et compositions les contenant, destinees au diagnostic et au traitement des infections par le virus hiv.
EP0300031A1 (de) Immunsuppressive peptide und verfahren zu ihrer anwendung
Brockhaus et al. Normal Salivary Mucin Contains the Gastrointestinal Cancer‐Associated Antigen Detected by Monoclonal Antibody 19–9 in the Serum Mucin of Patients 1
FR2502154A1 (fr) Procede de preparation d'antigenes de l'hepatite virale nanb, et application a la realisation d'un reactif permettant le diagnostic et le pronostic des infections provoquees par les virus des hepatites virales
Schenck et al. IgG subclass distribution of serum antibodies against lipopolysaccharide from Bacteroides gingivalis in periodontal health and disease
CA2304961A1 (en) Methods and compositions for binding hematopoietic stem cells
JPH09507754A (ja) 哺乳類悪性細胞の選択的メチオニン飢餓方法
Cormane et al. Immunologic implications of PUVA therapy in psoriasis vulgaris
WO1991012332A1 (fr) Anticorps monoclonaux reconnaissant un peptide associe a un antigene majeur d'histocompatibilite
WO2003068820A1 (fr) IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS
US5792455A (en) Anti-idiotypic antibody vaccines
Hiemstra et al. Clinical and immunological studies in patients with an increased serum IgD level
Lu et al. Immunosuppression by YAC-1 lymphoma: role of shed gangliosides
JPH03198795A (ja) 種々のヒト白血病およびリンパ腫細胞上に広く存在する特有の抗原に反応するモノクローナル抗体、および診断および治療を目的とした該抗体の使用法
FR2767324A1 (fr) Utilisation de proteines d'enveloppe recombinantes pour le diagnostic du virus de la dengue
JPH04501352A (ja) ナチュラルキラー細胞および非特異的細胞障害性細胞レセプターに対する抗体
CA1270778A (fr) Cellules hybrides secretant des anticorps anti- idiotypiques, anticorps monoclonaux secretes par lesdites cellules hybrides, leur preparation et leur application
EP1301791B1 (de) Vorrichtung und verfahren zum molekularen nachweis
BE1000587A4 (fr) Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b.
CA1197187A (fr) Procede et chaine reactionnelle pour le diagnostic de la leucose bovine enzootique
FR2599513A1 (fr) Anticorps monoclonaux inhibant la liaison de ige soluble aux lymphocytes humains, hybridomes monoclonaux produisant de tels anticorps, leur utilisation

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19950608